Rufinamide
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lennox-Gastaut Syndrome
Conditions
Lennox-Gastaut Syndrome
Trial Timeline
Jun 13, 2013 → Nov 2, 2022
NCT ID
NCT02175173About Rufinamide
Rufinamide is a pre-clinical stage product being developed by Eisai for Lennox-Gastaut Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02175173. Target conditions include Lennox-Gastaut Syndrome.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03778424 | Pre-clinical | Active |
| NCT02175173 | Pre-clinical | Completed |
| NCT01151540 | Phase 3 | Completed |
| NCT00448539 | Phase 3 | Terminated |
Competing Products
6 competing products in Lennox-Gastaut Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + Perampanel | Eisai | Phase 3 | 77 |
| Rufinamide (E2080) + Placebo | Eisai | Phase 3 | 77 |
| Rufinamide | Eisai | Phase 3 | 77 |
| Rufinamide + Any other approved Antiepileptic Drug | Eisai | Phase 3 | 77 |
| Clobazam | Lundbeck | Phase 3 | 74 |
| GWP42003-P | Jazz Pharmaceuticals | Approved | 82 |